Global Dry Powder Inhaler Market is set to experience a significant growth of 4.6% CAGR from 2021 to 2031, with an estimated market value of around US$ 18.9 Bn as of 2021. As per Future Market Insights’ projections, Manually Operated Inhaler Devices
According to Future Market Insights, the global market for dry powder inhaler is slated to exhibit a CAGR of nearly 4.6% during the forecast period (2021-2031), in terms of volume.
Data Points | Market Insights |
Market Value 2020 | US$ 18.1 Bn |
Market Value 2021 | US$ 18.9 Bn |
Market Value 2031 | US$ 29.6 Bn |
CAGR 2021-2031 | 4.6% |
Market Share of Top 5 Countries | 60.5% |
Key Market Players | GlaxoSmithKline Plc, AstraZeneca Plc, Novartis AG, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Cipla Limited, Chiesi Farmaceutici S.p.A., Elpen S.A., Vectura Group Plc, Beximco Pharmaceuticals Ltd., Hovione, AptarGroup, Inc., Iconovo AB (Stevanato Group), Sava Healthcare Ltd., MannKind Corporation, Mylan N.V(a part of Viatris) and Pharmaxis |
Over 4000,000 Mn units of dry powder inhaler are pegged to be sold across the globe by 2031-end.
Challenges Regarding Varying Characteristics of Dry Powder Inhalers to Pave Opportunities for Medical Device Manufacturers
Regulatory pressures and changes in drug delivery market have driven innovation of the dry powder inhaler forward.
According to the World Health Organization (WHO), nearly 300 Mn people worldwide are affected by asthma, and approximately 240 Mn from the chronic obstructive pulmonary disease (COPD).
Over half of these patients combined prefer use of dry powder inhalers for treatment of their disease.
These devices have depicted great potential in effective and reliable drug delivery, with novel designs ensuring the possibility to overcome future compliance, cost, and safety challenges.
Request a sample @
https://www.futuremarketinsights.com/reports/sample/rep-gb-5150
Some of the essential performance characteristics regarding dry powder inhalers are associated with dose-delivery, performances at varying airflows, and fine particle fraction content.
These characteristics may vary with respect to powder formulations, creating the need for fine tuning of the device or powder formulation or both combined for achieving optimal performance.
The requirement is particularly high in micro-dosing dry powder inhalers, which in turn is paving opportunities for medical device manufacturers in terms of innovations and advancements.
Growing adoption of unhealthy lifestyle, increasing geriatric population, and growing air pollution levels fuelling prevalence of various respiratory disorders are key factors driving expansion of the global dry powder inhaler market.
In addition, favorable government initiatives being taken across the globe for improving the healthcare infrastructure will further influence the market growth in the near future.
However, the fact that dry powder inhalers are not moisture-resistant remains a major challenge for manufacturers, as the medicine loses its properties when it comes in contact with the moisture.
Availability of effective alternatives such as nebulizers and electric pumps are expected to restrain adoption of dry powder inhalers.
Lack of awareness regarding these devices in low-income & underdeveloped countries may further hinder the market growth to a certain extent.
Ask For Customization@
https://www.futuremarketinsights.com/customization-available/rep-gb-5150
Key Research Findings from FMI’s Report on Dry Powder Inhaler Market
Leading companies in the global dry powder inhaler market are focusing on the development of new generation products.
These market players are making huge investments in R&D activities associated with novel device architectures, particle engineering, and powder formulations.
Development of improved particle properties, along with efficient inhaler designs is expected to remain key strategies among the market players. Key market participants profiled in the report include Vectura Group Plc, MannKind Corporation, Chiesi Farmaceutici S.p.A., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Limited, Cipla Ltd., Novartis AG, GlaxoSmithKline Plc, 3M Company, and Astrazeneca Plc.
Ask an Analyst@
https://www.futuremarketinsights.com/ask-question/rep-gb-5150
Key Market Segments Covered In Dry Powder Inhalers Industry Research
By Product :
By Indication :
By Function :
By End User :
By Region :
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market.
Oct 26, 2022